REPLIGEN CORP Deferred Income Tax Assets, Net
REPLIGEN CORP (RGEN) had Deferred Income Tax Assets, Net of $700.00 thousand as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:DeferredIncomeTaxAssetsNet · last filed 2026-07-29
- 2026-06-30: Deferred Income Tax Assets, Net $700.00K.
- 2026-03-31: Deferred Income Tax Assets, Net $1.36M.
- 2025-12-31: Deferred Income Tax Assets, Net $694.00K.
- 2025-09-30: Deferred Income Tax Assets, Net $856.00K.
| Period end | Deferred Income Tax Assets, Net |
|---|---|
| 2026-06-30 | $700.00K 10-Q · filed 2026-07-29 |
| 2026-03-31 | $1.36M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $694.00K 10-Q · filed 2026-07-29 |
| 2025-09-30 | $856.00K 10-Q · filed 2025-11-04 |
| 2025-06-30 | $800.00K 10-Q · filed 2025-08-07 |
| 2025-03-31 | $737.00K 10-Q · filed 2025-04-29 |
| 2024-12-31 | $749.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $101.00K 10-Q · filed 2024-11-18 |
| 2024-06-30 | $678.00K 10-Q/A · filed 2024-11-18 |
| 2024-03-31 | $866.00K 10-Q/A · filed 2024-11-18 |
| 2023-12-31 | $1.53M 10-K · filed 2025-03-14 |
| 2023-09-30 | $1.55M 10-Q/A · filed 2024-11-18 |
| 2023-06-30 | $1.76M 10-Q/A · filed 2024-11-18 |
| 2023-03-31 | $845.00K 10-Q/A · filed 2024-11-18 |
| 2022-12-31 | $840.00K 10-Q/A · filed 2024-11-18 |
| 2022-09-30 | $1.76M 10-Q · filed 2022-11-01 |
| 2022-06-30 | $1.91M 10-Q · filed 2022-08-02 |
| 2022-03-31 | $1.61M 10-Q · filed 2022-04-27 |
| 2021-12-31 | $1.90M 10-K · filed 2023-02-22 |
| 2021-09-30 | $1.54M 10-Q · filed 2021-10-28 |
| 2021-06-30 | $1.71M 10-Q · filed 2021-07-27 |
| 2021-03-31 | $2.00M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $2.48M 10-K · filed 2022-02-17 |
| 2020-09-30 | $2.19M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $4.83M 10-Q · filed 2020-07-30 |
| 2019-12-31 | $2.92M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |